Response to febuxostat according to clinical subtypes of hyperuricemia: a prospective cohort study in primary gout.

ABSTRACT:

Background

While xanthine oxidase inhibitors target uric acid production, renal urate underexcretion is the predominant subtypes in gout. This study was to compare treatment response to the XOI febuxostat in a gout cohort according to clinical subtypes of hyperuricemia.

Methods

A prospective cohort study was conducted to compare the efficacy and safety of febuxostat (initially 20 mg daily, escalating to 40 mg daily if not at target) in 644 gout patients with the three major clinical subtypes for 12 weeks. Hyperuricemia was defined as the renal overload subtype, the renal underexcretion subtype, or the combined subtype based on UUE > or ≤ 600 mg/d/1.73 m² and FE_UA < or ≥ 5.5%. The primary endpoint was the rate of achieving serum urate (SU) < 6 mg/dL at w

SUBMITTER: Qi H 

PROVIDER: S-EPMC10712161 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature